SCHEDULE 13G: BlackRock Discloses 5.3% Passive Stake in Entrada Therapeutics
Beneficial Ownership Statement
BlackRock, Inc. has reported a beneficial ownership of 5.3% of Entrada Therapeutics, Inc.'s common stock as of December 31, 2024, in a routine Schedule 13G filing.
Summary
- BlackRock, Inc. filed a Schedule 13G with the SEC, disclosing beneficial ownership of 1,974,452 shares of Entrada Therapeutics, Inc. common stock.
- This ownership represents 5.3% of the total outstanding common stock of Entrada Therapeutics, Inc.
- BlackRock holds sole voting power over 1,932,133 shares and sole dispositive power over all 1,974,452 shares.
- The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Entrada Therapeutics, Inc.
- Several BlackRock subsidiaries are identified as entities that acquired the security, including BlackRock Life Limited, BlackRock Advisors, LLC, Aperio Group, LLC, and BlackRock Institutional Trust Company, National Association.
Sentiment
Score: 5
Explanation: Neutral. A Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the issuer's performance or prospects. It simply indicates an institutional investment.
Future Outlook
NA
Industry Context
This filing is a standard disclosure by a large institutional investor, BlackRock, indicating a passive ownership stake in Entrada Therapeutics, Inc. Such filings are common for major asset managers who hold diversified portfolios and cross the 5% ownership threshold in various public companies. It does not imply any strategic or operational changes for Entrada Therapeutics, Inc. but rather reflects BlackRock's investment activities.
Stakeholder Impact
- For shareholders of Entrada Therapeutics, Inc., this filing indicates that a major institutional investor, BlackRock, holds a significant passive stake, which can be viewed as a vote of confidence in the company's long-term prospects by a large asset manager.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked. |
| 2024-12-31 | Date of event requiring the filing of this statement (beneficial ownership snapshot date). |
| 2025-01-21 | Date of execution of the new Power of Attorney. |
| 2025-02-04 | Date of filing of the Schedule 13G. |
Keywords
BlackRock, Entrada Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.